Skip to main content

ViPOR Results in Durable Remission in Specific Subtypes of Lymphoma

Medically reviewed by Carmen Pope, BPharm. Last updated on June 20, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, June 20, 2024 -- For patients with specific subtypes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), treatment with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) yields durable remission, according to a study published in the June 20 issue of the New England Journal of Medicine.

Christopher Melani, M.D., from the National Cancer Institute in Bethesda, Maryland, and colleagues performed a single-center, phase 1b to 2 study of a regimen of ViPOR in relapsed or refractory DLBCL. Twenty patients were included in phase 1b, 10 with DLBCL, which assessed four dose levels of venetoclax. A phase 2 expansion was conducted in 40 patients with germinal-center B-cell (GCB) and non-GCB DLBCL.

The researchers established venetoclax at a dose of 800 mg as the recommended phase 2 dose. All patients in phase 2 had toxic effects, including grade 3 or 4 neutropenia, thrombocytopenia, anemia, and febrile neutropenia (in 24, 23, 7 and 1 percent of the cycles, respectively). Overall, 54 percent of the evaluable patients with DLBCL had objective responses; complete responses occurred in 38 percent, which were exclusively in patients with non-GCB DLBCL and high-grade B-cell lymphoma with rearrangements of MYC and BCL2 or BCL6 (or both). At the end of ViPOR therapy, circulating tumor DNA was undetectable in 33 percent of the patients. Two-year progression-free and overall survival were 34 and 36 percent, respectively, with a median follow-up of 40 months.

"Although the efficacy of ViPOR in specific molecular subtypes limited the subgroup of patients with DLBCL who had potentially curable disease, this very specificity provides some confidence in the generalizability of our results," the authors write.

Genentech provided venetoclax and obinutuzumab and Bristol Myers Squibb-Celgene provided lenalidomide for the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Risk for Lymphoma, Skin Cancer Increased in Individuals With Tattoos

FRIDAY, March 7, 2025 -- Tattooed individuals have an increased risk for lymphoma and skin cancers, according to a study recently published in BMC Public Health. Signe Bedsted...

Obesity at Pediatric Cancer Diagnosis Linked to Inferior Survival

MONDAY, Jan. 13, 2025 -- Obesity at cancer diagnosis is associated with inferior survival among children aged 2 to 18 years, according to a study published online Jan. 13 in...

Position Statement Developed for Managing Blood Cancers in Pregnancy

WEDNESDAY, Jan. 8, 2025 -- In a new position statement published online Jan. 3 in The Lancet Haematology, guidelines are presented for the management of acute leukemia and...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.